GoAI
Get started
Quoin Pharmaceuticals, Ltd. logo

Quoin Pharmaceuticals, Ltd.

QNRX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$5.57

+$0.58 · +11.62%

Aug 21, 4:00 PM ET

QNRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

43

Fair Value

Momentum

19

Strong Down

Sentiment

58

Mixed

Risk resilience

26

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Michael Myers
Listed since
Aug 1, 2016
Employees
4

Market position

Day range

Current $5.57

52-week range

Current $5.57

Open
$5.44
Previous close
$4.99
Volume
71.85K
0.31× average
Average volume
233.25K
Average daily volume
Market cap
11.19M USD
Beta
1.66
Market reference 1
50-day average
$4.587
+21.43% above average
200-day average
$8.2098
-32.15% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-3.8B USD
P/E (TTM)
-0.39×
P/B (TTM)
2.84×
P/S (TTM)
0×
EV / EBITDA
241.74×
Earnings yield
-73.10%
Free cash flow yield
-62.63%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-120.47%
Return on assets
-77.51%
Return on invested capital
-109.75%

Financial health

Debt / equity
0×
Current ratio
3.61×

Financial statements

Income trends

Operating income

−16.29M USD-70.97%

Net income

−15.8M USD-76.34%
Income trends across reported periods−4.52M USD−10.68M USD−16.84M USD−23M USDOperating income, FY2021: −6.06M USDOperating income, FY2022: −9.26M USDOperating income, FY2023: −9.38M USDOperating income, FY2024: −9.53M USDOperating income, FY2025: −16.29M USDNet income, FY2021: −21.46M USDNet income, FY2022: −9.38M USDNet income, FY2023: −8.69M USDNet income, FY2024: −8.96M USDNet income, FY2025: −15.8M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −6.06M USD. Operating income FY2022 −9.26M USD. Operating income FY2023 −9.38M USD. Operating income FY2024 −9.53M USD. Operating income FY2025 −16.29M USD. Net income FY2021 −21.46M USD. Net income FY2022 −9.38M USD. Net income FY2023 −8.69M USD. Net income FY2024 −8.96M USD. Net income FY2025 −15.8M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development9.8M USD3.6M USD3.31M USD2.67M USD1.56M USD
Selling, general, and administrative6.49M USD5.93M USD6.07M USD6.58M USD4.5M USD
Operating expenses16.29M USD9.53M USD9.38M USD9.26M USD6.06M USD
Interest income482.08K USD558.49K USD694.61K USD95.75K USD—
Interest expense———714.08K USD1.09M USD
Depreciation and amortization100K USD100K USD103.71K USD104.04K USD104.04K USD
Operating income−16.29M USD−9.53M USD−9.38M USD−9.26M USD−6.06M USD
Net income−15.8M USD−8.96M USD−8.69M USD−9.38M USD−21.46M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-681.83%
11 comparable reports
Latest EPS result
-1.9
Estimate -1.83 · Miss by 3.83%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.43-5.6-10.77-15.94Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual -12.24, estimate -0.5, surprise -2348.00%, Miss. Q2 2025, reported May 13, 2025: actual -6.5, estimate -3.85, surprise -68.83%, Miss. Q3 2025, reported Aug 7, 2025: actual -6.28, estimate -6.83, surprise +8.05%, Beat. Q4 2025, reported Nov 6, 2025: actual -6.71, estimate -6.36, surprise -5.50%, Miss. Q1 2026, reported Mar 26, 2026: actual -14.8, estimate -6.42, surprise -130.53%, Miss. Q2 2026, reported May 7, 2026: actual -1.77, estimate -1.8, surprise +1.67%, Beat. Q3 2026, reported Aug 14, 2026: actual -1.9, estimate -1.83, surprise -3.83%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -1.53, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy4100%
Hold00%
Sell00%
Strong sell00%

QNRX news

globenewswire.com

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results

– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome –…

Read source
globenewswire.com

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026

ASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today…

Read source
globenewswire.com

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, with initiation expected in 2H 2026

Read source
globenewswire.com

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

Read source
globenewswire.com

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiate in the Second Half…

Read source
globenewswire.com

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN, Va., June 18, 2026…

Read source

QNRX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research QNRX

research.disclaimer